1.
Red blood cells treated with the amustaline (S-303) pathogen reduction system: a transfusion study in cardiac surgery
Brixner V, Kiessling A H, Madlener K, Muller M M, Leibacher J, Dombos S, Weber I, Pfeiffer H U, Geisen C, Schmidt M, et al
Transfusion. 2018;58((4):):905-916
Abstract
BACKGROUND Nucleic acid-targeted pathogen inactivation technology using amustaline (S-303) and glutathione (GSH) was developed to reduce the risk of transfusion-transmitted infectious disease and transfusion-associated graft-versus-host disease with red blood cell (RBC) transfusion. STUDY DESIGN AND METHODS A randomized, double-blind, controlled study was performed to assess the in vitro characteristics of amustaline-treated RBCs (test) compared with conventional (control) RBCs and to evaluate safety and efficacy of transfusion during and after cardiac surgery. The primary device efficacy endpoint was the postproduction hemoglobin (Hb) content of RBCs. Exploratory clinical outcomes included renal and hepatic failure, the 6-minute walk test (a surrogate for cardiopulmonary function), adverse events (AEs), and the immune response to amustaline-treated RBCs. RESULTS A total of 774 RBC unis were produced. Mean treatment difference in Hb content was -2.27 g/unit (95% confidence interval, -2.61 to -1.92 g/unit), within the prespecified equivalence margins (+/-5 g/unit) to declare noninferiority. Amustaline-treated RBCs met European guidelines for Hb content, hematocrit, and hemolysis. Fifty-one (25 test and 26 control) patients received study RBCs. There were no significant differences in RBC usage or other clinical outcomes. Observed AEs were within the spectrum expected for patients of similar age undergoing cardiovascular surgery requiring RBCs transfusion. No patients exhibited an immune response specific to amustaline-treated RBCs. CONCLUSION Amustaline-treated RBCs demonstrated equivalence to control RBCs for Hb content, have appropriate characteristics for transfusion, and were well tolerated when transfused in support of acute anemia. Renal impairment was characterized as a potential efficacy endpoint for pivotal studies of RBC transfusion in cardiac surgery.
2.
Treatment of Red Blood Cells with the INTERCEPT Blood System for pathogen inactivation for use in a double blinded phase III study preserves physiological erythrocyte morphology
Paranikulangara P, Brixner V, Dombos S, Weber I, Leibacher J, Heldke S, Graminske S, Ravanat C, Erickson A, North A, et al
Transfusion Medicine and Hemotherapy. 2016;43((Suppl. 1)):51.. p04-3 .
3.
Quality parameters of red blood cells treated with INTERCEPT pathogen inactivation system using S-303: A phase III clinical trial in cardiac surgery patients
Dombos S, Weber I, Brixner V, Pfeiffer H-U, Müller M, Geisen C, Leibacher J, Wotapek T, Janetzko K, Henschler R, et al
Transfusion Medicine and Hemotherapy. 2015;42((Suppl. 1)):5.. Abstract no. FV-02-3.
4.
Clinical safety and efficacy of red blood cell components treated with the second generation s-303 pathogen and leukocyte inactivation system – a randomized controlled double-blind phase 3 study in patients requiring transfusion support of acute anemia
Brixner V, Kiessling AH, Madlener K, Leibacher J, Muller M, Geisen C, Henschler R, North A, Huang N, Mufti N, et al
Transfusion Medicine and Hemotherapy. 2015;42((Suppl. 1)):4.. Abstract no. FV-02-1.
5.
Clinical safety and efficacy of red blood cell Components treated with the s-303 pathogen inactivation system a randomized controlled double-blind phase 3 study in patients requiring transfusion support of acute anemia
Brixner V, Kiessling AH, Madlener K, Leibacher J, Mueller MM, Geisen C, Henschler R, North A, Huang N, Mufti N, et al
Vox Sanguinis. 2015;109((Suppl. 1)):28.. Abstract No. 3C-S10-04.
6.
Red blood cells treated with the S-303 system for pathogen inactivation demonstrate in vitro characteristics suitable for transfusion: phase III clinical trial in cardiac surgery patients
Brixner V, Leibacher J, Pfeiffer H-U, Muller MM, Geisen C, Henschler R, Janetzko K, Heldke S, Huang N, Ernst C, et al
Vox Sanguinis. 2015;109((Suppl. 1)):185.. Abstract No. P-298.
7.
Quality parameters of red blood cells treated with intercept pathogen inactivation system using S-303: a phase III clinical trial in cardiac surgery patients
Leibacher J, Brixner V, Pfeiffer H-U, Muller MM, Geisen C, Dombos S, Weber I, Wotapek T, Janetzko K, Henschler R, et al
Vox Sanguinis. 2015;109((Suppl. 1)):194.. Abstract No. P-319.
